Answers are grounded in this paper and cite their sources.
A low-cost spiro[3.3]heptane-2,6-dispirofluorene-based HTM termed SDF-OMeTAD has been designed and synthesized via a two-step reaction, representing a considerable simplification with respect to that of the well-known spiro-OMeTAD.
No takes yet. Share an insight, caveat, or question.
Li et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: